Table 2 Demographics and patients’ information
N = 23 | |
|---|---|
Age, years, mean (SD) | 37.8 (14.7) |
Female, n (%) | 17 (73.9) |
HAE | |
Type I, n (%) | 22 (95.6) |
Type II, n (%) | 1 (4.3) |
HAE severitya | |
Moderate, n (%) | 12 (52.2) |
Severe, n (%) | 11 (47.8) |
Other HAE treatment before switching, n (%) | 23 (100) |
Icatibant (alternative to C1-INH for acute attacks) | 12 (52.2) |
Danazol (prophylaxis) | 17 (73.9) |
Stanozolol (prophylaxis) | 2 (8.7) |
Oxandrolone (prophylaxis) | 1 (4.3) |
Tranexamic acid (prophylaxis) | 14 (60.9) |
Previous treatment with C1-INH (Berinert®) 500 IU, n (%) | 21 (91.3) |
Adverse effects | 0 (0) |
Preparation/infusion time, minutes, mean (SD) (n = 18) | 16.9 (2.5) |
Training timeb, minutes, mean (SD) (n = 8) | 55.6 (6.2) |
Years before switching to 1500 IU, mean (SD) | 6.4 (3.9) |
Current treatment with C1-INH (Berinert®) 1500 IU, n (%) | 23 (100) |
Adverse effects | 1 (4.3) |
Preparation/infusion time, minutes, mean (SD) (n = 18) | 11.1 (2.7) |
Training timeb, minutes, mean (SD) (n = 6) | 45 (7.7) |
Years current treatment with 1500 IU, mean (SD) | 1 (0.49) |